BrUOG 351: PRE-OPERATIVE APBI USING NIBB

Breast Cancer Clinical Trial

— 351  

Official title:

BrUOG 351: Pre-Operative Accelerated Partial Breast Irradiation (APBI) Using Non-Invasive Image-Guided Breast Brachytherapy (NIBB)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03437915
• Other study ID #: BrUOG 351
• Status: Withdrawn
• Phase: N/A
• Start date: March 2019
• Est. completion date: January 21, 2020

Study information

• Verified date: March 2021
• Source: Brown University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Partial breast irradiation is typically performed after surgical removal of the tumor. Partial breast irradiation allows for focused radiation to the area from which the cancer was removed, sparing breast tissue from the potential bad effects of radiation compared to radiating the whole breast, which was the standard of care for many years. This study is evaluating the use of partial breast irradiation with NIBB performed before surgery instead of after surgery.This should allow researchers to target the cancer even more accurately and result in less normal breast tissue receiving radiation which may cause less side effects and/or a better cosmetic outcome.

In this study partial breast treatment will be given with NIBB in 5 treatments over about 1 week. Surgical removal of the tumor will then be performed between 4-12 weeks following radiation treatment. Researchers believe that participant's risk of complications from surgery will not be higher after getting these radiation treatments than it would have been if participants had surgery first, but that is one of the things researchers are studying.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 21, 2020
• Est. primary completion date: January 21, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Confirmed histological diagnosis of invasive breast carcinoma and/or DCIS (Invasive lobular carcinoma excluded);

• Age greater or equal to 60 years old;

• Life expectancy > 6 months;

• Candidate for breast conserving surgery who intends to undergo breast conserving surgery as confirmed in writing by treating physician in consultation with surgeon

• Clinically lymph node negative (cN0) as confirmed in writing by patient's treating physician. If patient has suspicious lymphadenopathy on imaging it is required that patient undergo a biopsy to confirm cN0.

• Tumor size by imaging = 2cm; (Tis or T1)

• Estrogen receptor positive if invasive disease (DCIS can be ER negative);

• Her2neu negative if invasive disease;

• Nuclear Grade 1 or 2 if invasive disease (DCIS can be Grade 3);

• ECOG performance status of 0-2 (Appendix 1);

• Informed consent signed.

Exclusion Criteria:

• Excisional biopsy or ipsilateral breast surgery within 6 months;

• Invasive lobular histology;

• Definitive LVSI on biopsy;

• Suspicious imaging findings suggesting multi-focal or multi-centric disease, unless biopsy proven benign;

• Paget's disease of the nipple

• Distant metastases;

• Known BRCA 1/2 Mutation

• Active lupus or scleroderma,;

• Psychiatric or addictive disorder that would preclude attending follow-up;

• Neoadjuvant chemotherapy or endocrine therapy (adjuvant therapy is permitted);

• Breast Implants;

• Tumor not well visualized on AccuBoost imaging;

• Breast separation with compression > 8cm at time of simulation.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Carcinoma in Situ
• Carcinoma, Ductal
• Carcinoma, Intraductal, Noninfiltrating
• Ductal Carcinoma in Situ
• Invasive Breast Cancer

Intervention

Radiation:
• NIBB: accuboost
28.5 Gy delivered in 5 daily fractions

Procedure:
• Partial mastectomy
4-12 weeks post NIBB

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
Jaroslaw Hepel	Brown University, Rhode Island Hospital, Women and Infants Hospital of Rhode Island

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of APBI including rate of surgical complications.		Surgery will occur 4-12 weeks post NIBB treatment
Primary	Toxicity of pre-op APBI including rate of surgical complications.	Defined as acute (during treatment and through 4 weeks post treatment)	Defined at up to 6 weeks post APBI
Primary	Toxicity of surgical complications		Surgery to occur 4-12 weeks post radiation and post-op complications collected through 3 months post surgery
Secondary	Assess and report late toxicity	Late toxicity defined as 6 weeks post NIBB through 3 years in follow-up	6 weeks post treatment through 3 years